The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PMVP | -18.01% | -95.94% | -47.27% | -96% |
| S&P | +11% | +85.61% | +13.15% | +100% |
PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in March 2013 and is headquartered in Princeton, NJ.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.03M | 91.4% |
| Market Cap | $74.19M | -3.4% |
| Market Cap / Employee | $1.58M | 0.0% |
| Employees | 47 | -25.4% |
| Net Income | -$21.06M | -9.5% |
| EBITDA | -$22.49M | -4.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $36.34M | -26.8% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.54M | -95.5% |
| Short Term Debt | $0.39M | -68.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -46.29% | -25.0% |
| Return On Invested Capital | -23.62% | -1.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$19.82M | -17.7% |
| Operating Free Cash Flow | -$19.82M | -17.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.39 | 0.32 | 0.34 | 0.53 | 47.32% |
| Price to Tangible Book Value | 0.39 | 0.32 | 0.34 | 0.53 | 47.32% |
| Enterprise Value to EBITDA | 3.58 | 4.77 | 3.77 | 2.41 | -44.64% |
| Return on Equity | -29.2% | -32.7% | -45.6% | -51.9% | 119.46% |
| Total Debt | $1.19M | $1.11M | $1.02M | $0.93M | -92.98% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
